Support By : Li-lab
| PATHWAY_NAME | REACTOME_ID | KEGG_ID | DRUG_NAME | PUBCHEM_CID | Datasource |
|---|---|---|---|---|---|
| RNA polymerase | R-HSA-73864 | map03020 | fludroxycortide | 15209 | drug-path |
| Glioma | Q9NZM4 | map05214 | 3-acetamidocoumarin | 136620 | drug-path |
| Natural killer cell mediated cytotoxicity | R-HSA-5218921 | map04650 | 3-acetamidocoumarin | 136620 | drug-path |
| Hematopoietic cell lineage | R-HSA-173752 | map04640 | 3-acetamidocoumarin | 136620 | drug-path |
| Pathways in cancer | R-HSA-9824443 | map05200 | 3-acetamidocoumarin | 136620 | drug-path |
| T cell receptor signaling pathway | R-HSA-983705 | map04660 | 3-acetamidocoumarin | 136620 | drug-path |
| Olfactory transduction | R-HSA-9751605 | map04740 | 3-acetamidocoumarin | 136620 | drug-path |
| Systemic lupus erythematosus | R-HSA-977105 | map05322 | 3-acetamidocoumarin | 136620 | drug-path |
| Pancreatic cancer | R-HSA-9700206 | map05212 | 3-acetamidocoumarin | 136620 | drug-path |
| Prostate cancer | R-HSA-2990872 | map05215 | 3-acetamidocoumarin | 136620 | drug-path |
| Acute myeloid leukemia | R-HSA-9680350 | map05221 | 3-acetamidocoumarin | 136620 | drug-path |
| Fc epsilon RI signaling pathway | R-HSA-2454202 | map04664 | 3-acetamidocoumarin | 136620 | drug-path |
| Bladder cancer | R-HSA-9700206 | map05219 | 3-acetamidocoumarin | 136620 | drug-path |
| ErbB signaling pathway | R-HSA-168638 | map04012 | 3-acetamidocoumarin | 136620 | drug-path |
| Non-small cell lung cancer | R-HSA-5619066 | map05223 | 3-acetamidocoumarin | 136620 | drug-path |
| Type II diabetes mellitus | R-HSA-2127377 | map04930 | 3-acetamidocoumarin | 136620 | drug-path |
| Small cell lung cancer | R-HSA-5619066 | map05222 | 3-acetamidocoumarin | 136620 | drug-path |
| Apoptosis | R-HSA-109581 | map04210 | 3-acetamidocoumarin | 136620 | drug-path |
| p53 signaling pathway | R-HSA-168638 | map04115 | 3-acetamidocoumarin | 136620 | drug-path |
| RNA polymerase | R-HSA-73864 | map03020 | 3-acetamidocoumarin | 136620 | drug-path |